ANN D RHOADS
CIK 1250252 · Chief Financial Officer · last filed 2026-06-29
ANN D RHOADS is a Chief Financial Officer who has filed 93 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for QDEL, was dated Jun 29, 2026. Across all open-market trades the lifetime net is −$2.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.80M
10
93
-$2.91M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QDEL | Director | 23,257 | $13.75 | $319.8K | $21.2K | 20 | 2026-06-29 |
| GMED | Director | 40,384 | $86.15 | $3.48M | -$3.05M | 22 | 2026-06-08 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 0 | $2.65 | $0 | $80.0K | 7 | 2026-01-28 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | Director | — | $10.15 | — | $0 | 7 | 2025-08-29 |
| Evoke Pharma Inc (EVOK) Delisted | Director | — | $11.00 | — | $0 | 3 | 2021-07-23 |
| Forty Seven, Inc. (FTSV) Delisted | Chief Financial Officer | 0 | — | — | -$183.6K | 3 | 2020-04-07 |
| IRIX | Director | 5,690 | $0.84 | $4.8K | $0 | 3 | 2018-06-15 |
| Evoke Pharma Inc (OMED) Delisted | Director | — | — | — | $0 | 5 | 2018-04-27 |
| ZOGENIX, INC. (ZGNX) Delisted | EVP, CFO, Treasurer & Sec. | 24,901 | $26.68 | $664.4K | $220.8K | 11 | 2016-03-16 |
| NOVELLUS SYSTEMS INC (NVLS) Delisted | Director | 8,750 | — | — | $0 | 5 | 2011-05-13 |
Recent Filings
93 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-29 | QDEL | Grant (A) | — | $0 | EDGAR |
| 2026-06-08 | GMED | Exer (M) | +25,000 | $656.8K | EDGAR |
| 2026-06-02 | QDEL | Mixed | +6,829 | $0 | EDGAR |
| 2026-05-27 | QDEL | Mixed | +1,407 | $0 | EDGAR |
| 2026-01-28 | Repare Therapeutics Inc. (RPTX) Delisted | Disp (D) | −4,000 | $0 | EDGAR |
| 2026-01-23 | GMED | Grant (A) | — | $0 | EDGAR |
| 2025-12-10 | QDEL | Buy (P) | +750 | $21.2K | EDGAR |
| 2025-11-10 | GMED | Notice (144) | −2,000 | -$170.0K | EDGAR |
| 2025-11-10 | GMED | Sell (S) | −10,000 | -$818.0K | EDGAR |
| 2025-11-07 | GMED | Notice (144) | −8,000 | -$647.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.